問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Urology

Division of Hematology & Oncology

MacKay Memorial Hospital (在職)

Division of General Surgery

Division of General Surgery

Chi Mei Medical Center (在職)

Division of Urology

Chi Mei Medical Center (在職)
MacKay Memorial Hospital

Division of General Surgery

更新時間：2023-09-19

劉建良
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉建良

List

27Cases

2024-01-01 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-03-01 - 2032-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

-

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2017-09-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated11Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2014-11-06 - 2024-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2016-08-01 - 2020-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

2021-08-01 - 2028-01-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2018-12-01 - 2024-12-31

Phase III

Completed
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER

  • Condition/Disease

    EARLY HER2-POSITIVE BREAST CANCER

  • Test Drug

    Atezolizumab

Participate Sites
5Sites

Terminated4Sites

王惠暢
China Medical University Hospital

Division of General Surgery

2017-09-01 - 2023-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

2014-01-01 - 2024-03-11

Phase III

Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naive Subjects with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

  • Condition/Disease

    Prostate Cancer

  • Test Drug

    enzalutamide

Participate Sites
9Sites

Terminated9Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB